03:45:43 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-09-22 Kvartalsrapport 2023-Q2
2023-06-09 Årsstämma 2023
2023-04-21 Bokslutskommuniké 2022
2022-09-22 Kvartalsrapport 2022-Q2
2022-06-09 Ordinarie utdelning EXTX 0.00 NOK
2022-06-08 Årsstämma 2022
2022-04-27 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020


ListaMERK Equities
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.
2021-12-21 08:00:00
EXACT Therapeutics AS Awarded NOK 7.4 M Grant for the Development of its Next
Generation Ultrasound Transducer and Navigation System for ACT®

OSLO/ LONDON: 21 December 2021: EXACT Therapeutics AS ("EXACT-Tx" or "the
Company", Euronext Growth: EXTX), a clinical-stage precision health company
developing the Acoustic Cluster Therapy (ACT®), a proprietary
ultrasound-mediated drug delivery platform to enhance the efficacy of therapies
across multiple diseases, today announces the award of a research and innovation
grant from the Norwegian Research Council (NRC) of NOK 7.4 million for its
research-based project "Ultrasound Transducer for Acoustic Cluster Therapy."

The funding will support the Company's work with its partner GE Healthcare for
the development of a next-generation, bespoke, dual-frequency transducer
(ultrasound probe) and a precision navigation system to help guide the ACT®
procedure for targeted drug delivery in patients to allow real-time monitoring
by medical professionals in the clinical setting.

Dr Masha Strømme, Executive Chair of the Board, commented: "We are delighted to
receive this recognition from the Norwegian Research Council, which is a
testament to EXACT-Tx's innovative approach to therapeutic enhancement. The
development of the navigation system and dual-frequency probe will enhance the
ease of use of ACT® which will help its deployment across indications and, in
combination with, a wide range of therapeutic agents. This funding will
accelerate our journey towards becoming a leading precision health company."


For more information, please contact:

Dominic Moreland
EXACT Therapeutics
Email: dominic@exact-tx.com

Optimum Strategic Communications
Hollie Vile/ Manel Mateus/ Vici Rabbetts
Tel: +44 (0) 208 078 4357
Email: Exact@optimumcomms.com

About EXACT-Tx
EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to significantly amplify the clinical
utility of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and brain diseases. www.exact-tx.com

About ACT®
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.
o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the Company is oncology, however the ACT® platform has
potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and
product classes.

Forward looking statements
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.